Browsing Tag
acquired hypothalamic obesity
3 posts
Rhythm Pharmaceuticals (RYTM) TRANSCEND trial in NEJM shows 19.8% placebo-adjusted BMI reduction
Rhythm Pharma (RYTM) TRANSCEND Phase 3 published in NEJM validates IMCIVREE for acquired hypothalamic obesity. 10,000-patient US market launch trajectory ahead.
Is setmelanotide the first true disease-targeted therapy for hypothalamic obesity?
Is setmelanotide redefining hypothalamic obesity treatment? Explore what Rhythm Pharmaceuticals, Inc.’s EU approval means for markets and growth.
Rhythm Pharmaceuticals’ IMCIVREE hits regulatory speed bump as FDA extends decision timeline into 2026
Find out how Rhythm Pharmaceuticals’ IMCIVREE FDA review delay could shape the rare obesity treatment market in 2026.